Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version

International Journal of Clinical Oncology

Volumn 13, Issue 5, 2008, Pages 416-430

  Nishida, Toshirou ^a   Hirota, Seiichi ^b   Yanagisawa, Akio ^c   Sugino, Yoshinori ^d   Minami, Manabu ^e   Yamamura, Yoshitaka ^f   Otani, Yoshihide ^g   Shimada, Yasuhiro ^h   Takahashi, Fumiaki ⁱ   Kubota, Tetsuro ^j  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ KITASATO UNIVERSITY   (Japan)

^j KEIO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Clinical practice guideline; Diagnosis; Gastrointestinal stromal tumor (GIST); KIT protein; Therapeutics

Indexed keywords

CONTRAST MEDIUM; DESMIN; DIATRIZOATE; FLUORODEOXYGLUCOSE; IMATINIB; PLACEBO; PROTEIN S 100; STEM CELL FACTOR; SUNITINIB;

ALGORITHM; ARTIFICIAL EMBOLISM; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ENDOSCOPIC ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOREACTIVITY; JAPAN; LAPAROSCOPIC SURGERY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 54849442097     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0798-7     Document Type: Review

References (49)

1. G.D. Demetri R.S. Benjamin C.D. Blanke NCCN Task Force 2007 NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines J Natl Compr Canc Netw 5 Suppl2 S1 S29
2. J.Y. Blay S. Bonvalot P. Casali 2005 Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 566 578
3. T. Kubota 2006 Gastrointestinal stromal tumor (GIST) and imatinib Int J Clin Oncol 11 184 189
4. The GIST Guideline Subcommittee of the Clinical Practice Guideline Committee for Cancer of JSCO (eds) (2008) Japanese clinical practice guidelines for GIST (1st edn). Kanehara, Tokyo, http://jsco-cpg.jp/item/03/index.html
5. S. Hirota K. Isozaki Y. Moriyama 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580
6. M. Miettinen L.H. Sobin M. Sarlomo-Rikala 2000 Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with reference to CD117 (KIT) Mod Pathol 13 1134 1142
7. M.C. Heinrich C.L. Corless A. Duensing 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710
8. S. Hirota A. Ohashi T. Nishida 2003 Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 660 667
9. K. Pauls S. Merkelbach-Bruse D. Thal 2005 PDGFRalpha-and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features Histopathology 46 166 175
10. H. Sihto M. Sarlomo-Rikala O. Tynninen M. Tanner 2005 KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors J Clin Oncol 23 49 57
11. M.C. Heinrich C.L. Corless G.D. Demetri 2003 Kinase mutation and imatinib response in patients with metastatic gastrointestinal stromal tumors J Clin Oncol 21 4342 4349
12. C. Tarni E. Merkel A.A. Canutescu 2005 Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling Clin Cancer Res 11 3668 3677
13. C.D. Fletcher J.J. Berman C. Corless 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459 465
14. N.A.C.S. Wong R. Young R.D.G. Malcomson 2000 Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach Histopathology 47 2247 2253
15. S. Singer B.P. Rubin M.L. Lux 2002 Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 3898 3905
16. Y. Fujimoto Y. Nakanishi K. Yoshimura T. Shimoda 2003 Clinicopathologic study of primary malignant gastrointestinal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients Gastric Cancer 6 39 48
17. T. Hasegawa Y. Matsuno T. Shimoda S. Hirohashi 2002 Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade Hum Pathol 33 669 676
18. N.C. Jhala D. Jhala I. Eltoum 2004 Endoscopic ultrasoundguided fine-needle aspiration biopsy: a powerful tool to obtain samples from small lesions Cancer 102 239 246
19. M. Arima N. Harada T. Kozu 1999 Endoscopic ultrasonography-guided fine needle aspiration biopsy for upper gastrointestinal diseases Endoscopia Digestiva 11 91 100
20. U. Tateishi T. Hasegawa M. Satake 2003 Gastrointestinal stromal tumor: correlation of computed tomography findings with tumor grade and mortality J Comput Assist Tomogr 27 792 798
21. H.C. Kim J.M. Lee K.W. Kim 2004 Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy AJR Am J Roentgenol 183 893 898
22. H. Choi C. Charnsangavej S. de Castro Faria 2004 CT Evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 1619 1628
23. G. Antoch J. Kanja S. Bauer 2002 Comparison of PET, CT and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumor J Nucl Med 45 357 365
24. 18FDG-PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 17 21
25. S. Shanker E. van Sonnenberg J. Desai 2005 Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate Radiology 235 892 898
26. R.P. DeMatteo J.J. Lewis D. Leung 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 58
27. Y. Fong D.G. Coit J.M. Woodruff 1993 Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients Ann Surg 217 72 77
28. R.P. DeMatteo M.C. Heinrich W.M. El-Rifai G. Demetri 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466 477
29. S.Q. Nguyen C.M. Divino J.L. Wang S.H. Dikman 2006 Laparoscopic management of gastrointestinal stromal tumors Surg Endosc 20 713 716
30. Y. Otani T. Furukawa M. Yoshida 2006 Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases Surgery 139 484 492
31. Y.W. Novitsky K.W. Kercher R.F. Sing 2006 Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors Ann Surg 243 738 745
32. J. Nishimura K. Nakajima T. Omori 2007 Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs open resection Surg Endosc 21 875 878
33. T. Takahashi K. Nakajima A. Nishitani 2007 An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors Int J Clin Oncol 12 369 374
34. A.T. van Oosterom I. Judson J. Verweij 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421 1423
35. G.D. Demetri M. Von Mehren C.D. Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480
36. J. Verweij P.G. Casali J. Zalcberg 2004 Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial Lancet 364 1127 1134
37. C.D. Blanke C. Rankin G.D. Demetri 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626 632
38. J.R. Zalcberg J. Verweij P.G. Casali 2005 Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg Eur J Cancer 41 1751 1757
39. J.Y. Blay A. Le Cesne I. Ray-Coquard 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 1107 1113
40. M.C. Heinrich C.L. Corless C.D. Blanke 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 4764 4774
41. G.D. Demetri A.T. van Oosterom C.R. Garrett 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338
42. Z9001. A phase III randomized double-blind study of adjuvant STI571 (Gleevec™) versus placebo in patients following the resection of primary gastrointestinal stromal tumor (GIST). Available at: https://www.acosog.org/ announcements/ACOSOG_Z9001A4_ Protocol_20050601.pdf
43. S. Bauer J.T. Hartmann M. de Wit 2005 Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 117 316 325
44. C.P. Raut M. Posner J. Desai 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 2331
45. P. Rutkowski Z. Nowecki P. Nyckowski 2006 Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate J Surg Oncol 93 304 311
46. R.P. DeMatteo R.G. Maki S. Singer 2007 Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 347 352
47. M. Van Glabbeke J. Verweij P.G. Casali 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 5795 5804
48. A. Gronchi M. Fiore F. Miselli 2007 Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 341 346
49. J. Hasegawa T. Kanda S. Hirota 2007 Surgical interventions for focal progression of advanced gastrointestinal stromal tumors under imatinib therapy Int J Clin Oncol 12 212 217